

Table 3.1
Verified Outcomes (Annualized Percentages) by Age at Enrollment for MRC Super Cohort Participants¹

Data as of: March 1, 2019; Events through March 1, 2019

Outcomes	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Number randomized	44174	6788	9352	19418	8616
Mean follow-up (months)	177.3	189.1	190.0	178.4	151.5
Cardiovascular					
CHD ²	3547 (0.54%)	241 (0.23%)	441 (0.30%)	1676 (0.58%)	1189 (1.09%)
CHD death ³	1556 (0.24%)	63 (0.06%)	142 (0.10%)	679 (0.24%)	672 (0.62%)
Clinical MI	2427 (0.37%)	188 (0.18%)	339 (0.23%)	1190 (0.41%)	710 (0.65%)
Angina ⁴	1625 (0.47%)	114 (0.20%)	226 (0.30%)	785 (0.52%)	500 (0.76%)
CABG/PTCA	3016 (0.46%)	246 (0.23%)	501 (0.34%)	1545 (0.54%)	724 (0.67%)
Carotid artery disease	521 (0.08%)	25 (0.02%)	82 (0.06%)	285 (0.10%)	129 (0.12%)
Congestive heart failure, WHI ⁴	1246 (0.36%)	84 (0.15%)	145 (0.19%)	531 (0.35%)	486 (0.74%)
Heart failure, UNC ⁵	2911 (0.45%)	184 (0.17%)	318 (0.22%)	1377 (0.48%)	1032 (0.97%)
Stroke	2839 (0.44%)	184 (0.17%)	346 (0.23%)	1379 (0.48%)	930 (0.85%)
PVD	674 (0.10%)	44 (0.04%)	102 (0.07%)	349 (0.12%)	179 (0.16%)
DVT	1111 (0.17%)	95 (0.09%)	192 (0.13%)	538 (0.19%)	286 (0.26%)
Pulmonary embolism	896 (0.14%)	86 (0.08%)	158 (0.11%)	440 (0.15%)	212 (0.19%)
DVT/PE	1601 (0.25%)	134 (0.13%)	278 (0.19%)	789 (0.27%)	400 (0.37%)
Coronary disease ⁶	7459 (1.14%)	564 (0.53%)	1043 (0.70%)	3538 (1.23%)	2314 (2.13%)
Aortic aneurysm ⁷	62 (0.04%)	4 (0.01%)	8 (0.02%)	39 (0.06%)	11 (0.06%)
Valvular heart disease ⁷	448 (0.29%)	27 (0.10%)	64 (0.17%)	250 (0.37%)	107 (0.59%)
Total cardiovascular disease⁸	10355 (1.59%)	755 (0.71%)	1453 (0.98%)	4924 (1.71%)	3223 (2.96%)
Cancer					
Breast cancer	2918 (0.45%)	438 (0.41%)	666 (0.45%)	1323 (0.46%)	491 (0.45%)
Invasive breast cancer	2393 (0.37%)	339 (0.32%)	545 (0.37%)	1077 (0.37%)	432 (0.40%)
In-situ breast cancer	580 (0.09%)	105 (0.10%)	132 (0.09%)	276 (0.10%)	67 (0.06%)
Ovarian cancer	273 (0.04%)	26 (0.02%)	56 (0.04%)	139 (0.05%)	52 (0.05%)
Endometrial cancer ⁹	330 (0.09%)	53 (0.09%)	85 (0.10%)	142 (0.09%)	50 (0.08%)
Colorectal cancer	930 (0.14%)	85 (0.08%)	148 (0.10%)	456 (0.16%)	241 (0.22%)
Other cancer ¹⁰	4134 (0.63%)	394 (0.37%)	733 (0.50%)	2039 (0.71%)	968 (0.89%)
Total cancer	7968 (1.22%)	928 (0.87%)	1585 (1.07%)	3782 (1.31%)	1673 (1.54%)
Fractures					
Hip fracture	1531 (0.23%)	52 (0.05%)	134 (0.09%)	679 (0.24%)	666 (0.61%)
Deaths					
Cardiovascular deaths	3450 (0.53%)	139 (0.13%)	317 (0.21%)	1495 (0.52%)	1499 (1.38%)
Cancer deaths	3064 (0.47%)	245 (0.23%)	467 (0.32%)	1515 (0.52%)	837 (0.77%)
Other known cause	3221 (0.49%)	154 (0.14%)	323 (0.22%)	1505 (0.52%)	1239 (1.14%)
Unknown cause	95 (0.01%)	6 (0.01%)	13 (0.01%)	52 (0.02%)	24 (0.02%)
Not yet adjudicated	356 (0.05%)	21 (0.02%)	50 (0.03%)	187 (0.06%)	98 (0.09%)
Total death¹¹	16349 (2.00%)	875 (0.63%)	1857 (1.00%)	7481 (2.09%)	6136 (4.54%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2020.

³ "CHD death" includes definite and possible CHD death.

⁴ Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2020. Reported statistics represent experience during the original program.

⁵ Definite or possible decompensated heart failure adjudicated by UNC.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure are not collected in the WHI Extension Studies 2005-2020.

⁷ Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2020.

⁸ Total CVD does not include aortic aneurysm or valvular heart disease.

⁹ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

¹⁰ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

¹¹ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.